The mRNA expression profile [Case (371): Primary Site (Liver and intrahepatic bile ducts), Program (TCGA), Project (TCGA-LIHC), Disease Type (Adenomas and adenocarcinomas); Files (530): Data Category (Transcriptome profiling), Workflow Type(HTSeq - Counts), Data Type (Gene Expression Quantification)], miRNA expression information [Case (373): Primary Site (liver and intrahepatic bile ducts), Program (TCGA),Project (TCGA-LIHC), Disease Type (Adenomas and adenocarcinomas); Files(425): Data Category (Transcriptome profiling), Data Type (Isoform Expression Quantification), Workflow Type(BCGSC miRNA Profiling)]and clinicopathological data[Case (377): Primary Site (liver and intrahepatic bile ducts); Files(423): Data Category: Clinical, Data Format: BCR XML] (Table (Table1)1) were obtained from TCGA ( database. And, the mRNA expression profile included 374 tumor samples and 50 non-tumor controls while miRNA expression profile contained 375 tumor samples and 50 normal controls. Subsequently, we downloaded all mature miRNA sequences (Fasta format, mature.fa) from the miRbase (, then expression profile for each mature miRNA of HCC were obtained by Perl language through combining two sets of data. Independent validation cohort was obtained from GEO ( database. The key words of 'hepatocellular carcinoma' and 'miRNA' were performed to screen out relevant dataset. And then, GSE63046 based on GPL11154 platform was selected. The gene expression profile includes 24 HCC patients and 24 unaffected tissues adjacent to tumors. Besides, we selected frozen plasma from 31 patients who undergone the hepatectomy and were initially diagnosed with HCC based on pathological biopsy at the Department of Abdominal Surgery of Yunnan Cancer Hospital from January 2020 to May 2020 as the HCC group for validation. No chemoradiotherapy or immunotherapy was received before the operation, and no other malignant tumor was observed. On the other hand, a total of 40 healthy physical examination patients and 18 patients with cirrhosis were enrolled as the normal group and benign group respectively. This study was approved by the ethics committee of Yunnan Cancer Hospital, and the enrolled patients have completed the informed consent.

Clinical characteristics of HCC patients.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.